Apalutamide, Darolutamide and Enzalutamide for nmCRPCIr al contenidoOncologíaApalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review Cattrini, C.; Caffo, O. et al.Cancers 2022, 14, 1792. https://doi.org/10.3390/cancers14071792Contenido relacionadoGuías EAU 2023Cáncer de próstataDarolutamide and Survival in mHSPCCPHSmDarolutamide + ADT + Docetaxel in mHSPC by SubgroupsCPHSm
